IL75400A - Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same - Google Patents

Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same

Info

Publication number
IL75400A
IL75400A IL75400A IL7540085A IL75400A IL 75400 A IL75400 A IL 75400A IL 75400 A IL75400 A IL 75400A IL 7540085 A IL7540085 A IL 7540085A IL 75400 A IL75400 A IL 75400A
Authority
IL
Israel
Prior art keywords
dialkoxypyridine
benzimidazoles
sulfinyl
sulfonyl
methyl
Prior art date
Application number
IL75400A
Other languages
English (en)
Other versions
IL75400A0 (en
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25691679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL75400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of IL75400A0 publication Critical patent/IL75400A0/xx
Publication of IL75400A publication Critical patent/IL75400A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/52—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL75400A 1984-06-16 1985-06-04 Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same IL75400A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH290184 1984-06-16
CH289984 1984-06-16

Publications (2)

Publication Number Publication Date
IL75400A0 IL75400A0 (en) 1985-10-31
IL75400A true IL75400A (en) 1988-10-31

Family

ID=25691679

Family Applications (1)

Application Number Title Priority Date Filing Date
IL75400A IL75400A (en) 1984-06-16 1985-06-04 Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same

Country Status (22)

Country Link
US (1) US4758579A (pt)
EP (1) EP0166287B1 (pt)
AU (1) AU578703B2 (pt)
BG (1) BG61322B2 (pt)
CA (1) CA1254215A (pt)
CY (1) CY1670A (pt)
CZ (1) CZ281242B6 (pt)
DE (2) DE3572488D1 (pt)
DK (1) DK170440B1 (pt)
ES (1) ES8705875A1 (pt)
GR (1) GR851399B (pt)
HK (1) HK86894A (pt)
IE (1) IE58117B1 (pt)
IL (1) IL75400A (pt)
LU (1) LU88700I2 (pt)
MY (1) MY103021A (pt)
NL (1) NL950030I2 (pt)
NZ (1) NZ212415A (pt)
PH (2) PH21850A (pt)
PT (1) PT80641B (pt)
SG (1) SG80192G (pt)
SK (1) SK278401B6 (pt)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW4585A1 (en) * 1984-04-19 1985-11-20 Hoffmann La Roche Imidazole derivatives
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
NZ220022A (en) * 1986-04-22 1990-04-26 Byk Gulden Lomberg Chem Fab 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3621215A1 (de) * 1986-06-25 1988-01-07 Bayer Ag Fluorhaltige o-phenylendiamine und o-aminophenole
EP0370056A1 (de) * 1987-07-16 1990-05-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue diazole
AU2817989A (en) * 1987-12-11 1989-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel benzimidazole derivatives
DE4018642C2 (de) * 1990-06-11 1993-11-25 Byk Gulden Lomberg Chem Fab Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
FR2665158B1 (fr) * 1990-07-30 1993-12-24 Air Liquide Clathrates de peroxyacides.
DE69132082T2 (de) * 1990-10-17 2000-08-31 Takeda Chemical Industries, Ltd. Pyridin-Derivate, Verfahren zu deren Herstellung und Anwendung
CA2138787A1 (en) * 1992-07-08 1994-01-20 Clifton Augustus Baile Alleviating stomach ulcers in swine
EP0695123A4 (en) * 1993-04-27 1996-09-11 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING GASTRICAL FAULTS USING OPTICALLY PURE PANTOPRAZOLS
WO1994025028A1 (en) * 1993-04-27 1994-11-10 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (+) pantoprazole
AU4504000A (en) * 1993-04-27 2000-09-07 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
TW280770B (pt) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
CN1045773C (zh) * 1994-06-23 1999-10-20 沈阳药科大学 吡啶衍生物的制备方法
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
AU6998796A (en) * 1995-09-21 1997-04-28 Pharma Pass Llc Novel composition containing an acid-labile benzimidazole and process for its preparation
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6599927B2 (en) 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
US6051570A (en) * 1997-05-30 2000-04-18 Dr. Reddy's Research Foundation Benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
DE19745692A1 (de) * 1997-07-24 1999-01-28 Bayer Ag Verfahren zur Herstellung von 2-Chlor-benzimidazol-Derivaten
ATE281178T1 (de) 1997-07-25 2004-11-15 Altana Pharma Ag Protonenpumpenhemmer als kombinationstherapeutika mit antibakterielle wirkenden substanzen
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
CN1195500C (zh) 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
WO2000000474A1 (en) * 1998-06-26 2000-01-06 Russinsky Limited Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds
DE69905171T2 (de) * 1998-08-10 2003-11-20 Dept Of Veterans Affairs Washi Prodrugs für proton-pump-inhibitoren
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
ATE321538T1 (de) 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
YU86001A (sh) 1999-06-07 2004-07-15 Altana Pharma Ag. Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
ES2185459B1 (es) 2000-10-02 2003-12-16 Dinamite Dipharma Spa Procedimiento para la obtencion de pantoprazol y compuestos intermedios para el mismo.
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
PT1341524E (pt) 2000-12-07 2011-12-30 Nycomed Gmbh Preparação farmacêutica na forma de uma pasta compreendendo um ingrediente activo lábil a ácido
ES2403238T3 (es) 2000-12-07 2013-05-16 Takeda Gmbh Preparación farmacéutica en forma de una suspensión que comprende un ingrediente activo lábil en medio ácido
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
WO2002080762A1 (en) * 2001-04-06 2002-10-17 Medic4All Inc. A physiological monitoring system for a computational device of a human subject
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CN1243749C (zh) * 2001-09-18 2006-03-01 泽里新药工业株式会社 苯并咪唑衍生物
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
AU2003246791A1 (en) 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
ATE553103T1 (de) 2002-12-06 2012-04-15 Nycomed Gmbh Verfahren zur herstellung von (s)-pantoprazol
AU2003289948B2 (en) 2002-12-06 2009-12-24 Takeda Gmbh Process for preparing optically pure active compounds
JP2006514108A (ja) * 2002-12-19 2006-04-27 テバ ファーマシューティカル インダストリーズ リミティド パントプラゾールナトリウムの固体状態、それらの調製方法、及び公知のパントプラゾールナトリウム水和物の調製方法
WO2004063188A1 (en) * 2003-01-15 2004-07-29 Cipla Limited Paharmaceutical process and compounds prepared thereby
US20040235904A1 (en) * 2003-03-12 2004-11-25 Nina Finkelstein Crystalline and amorphous solids of pantoprazole and processes for their preparation
US7608625B2 (en) * 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2004101533A1 (en) * 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
WO2004111029A2 (en) * 2003-06-10 2004-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
NZ544173A (en) * 2003-07-15 2009-04-30 Alevium Pharmaceuticals Inc Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
WO2005074929A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
US20070060621A1 (en) * 2004-02-18 2007-03-15 Hughes Patrick M Methods and compositions for the administration of prodrugs of proton pump inhibitors
EP1715854A2 (en) * 2004-02-18 2006-11-02 Allergan, Inc. Prodrugs for the intravenous administration of proton pump inhibitors
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
BRPI0510251A (pt) * 2004-04-28 2007-10-23 Altana Pharma Ag derivados de dialcóxi-imidazopiridina
PT1746980E (pt) * 2004-05-07 2012-01-25 Nycomed Gmbh Forma de dosagem farmacêutica compreendendo granulados assim como o seu processo de fabrico
TW200613301A (en) * 2004-06-15 2006-05-01 Altana Pharma Ag Novel amino-halogen-imidazopyridines
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
KR20070109985A (ko) 2004-11-22 2007-11-15 아나디스 리미티드 생물활성 조성물
WO2006064249A2 (en) * 2004-12-16 2006-06-22 Cipla Limited Process for the preparation of pantoprazole sodium
EP1893602A2 (en) * 2005-05-06 2008-03-05 Medichem, S.A. Pantoprazole free acid form iii
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
EP1747776A1 (en) 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
WO2007026188A1 (en) * 2005-09-01 2007-03-08 Wockhardt Limited Process for the manufacture of antiulceratives
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007074856A1 (ja) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤の製造法
WO2007086077A2 (en) * 2006-01-24 2007-08-02 Unichem Laboratories Limited A novel one pot process for preparation of pantoprazole sodium sesquihydrate
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
CN101442985A (zh) * 2006-05-09 2009-05-27 阿斯利康(瑞典)有限公司 在其最终容器中被电离辐射灭菌了的包含质子泵抑制剂的肠胃外制剂
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007146341A2 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of pantoprazole magnesium salt
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
PL2046334T3 (pl) * 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
HUE046465T2 (hu) 2006-12-22 2020-03-30 Ironwood Pharmaceuticals Inc Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére
CN101631768A (zh) * 2007-03-15 2010-01-20 太阳医药高级研究有限公司 新型前药
EP2181106A1 (en) * 2007-07-17 2010-05-05 Ranbaxy Laboratories Limited Process for the preparation op pantoprazole sodium and pantoprazole sodium sesquihydrate
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CA2740095A1 (en) * 2008-10-10 2010-04-15 Celtaxsys, Inc. Method of inducing negative chemotaxis
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
WO2014113377A1 (en) 2013-01-15 2014-07-24 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
US20160115136A1 (en) * 2013-03-13 2016-04-28 University Of Iowa Research Foundation Compounds, compositions comprsing same, and methods related thereto
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
CN110487918B (zh) * 2018-05-14 2022-02-08 中国医学科学院药物研究所 泮托拉唑钠及其起始原料中基因毒性杂质的分析方法
AU2020354581A1 (en) 2019-09-24 2022-03-03 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
EP4204422A1 (en) 2020-08-26 2023-07-05 Syngenta Crop Protection AG Process for the preparation of 2,2-difluoro-1,3-benzodioxole derivatives with sulfur containing substituents
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234058A (pt) * 1968-10-21 1971-06-03
PH16240A (en) * 1978-04-11 1983-08-11 Smith Kline French Lab Process for making histamine antagonist
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
ZA825106B (en) * 1981-08-13 1983-04-27 Haessle Ab Novel pharmaceutical compositions
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
IL71664A (en) * 1983-05-03 1987-11-30 Byk Gulden Lomberg Chem Fab Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same
HU191756B (en) * 1983-05-03 1987-04-28 Byk Gulden Lomberg Chem Fab Process for preparing new fluoro-alkoxy-benzimidazole derivatives
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
NL950030I1 (pt) 1996-02-01
CS396491A3 (en) 1992-09-16
PH21850A (en) 1988-03-25
LU88700I2 (fr) 1996-04-29
DE19475025I2 (de) 2009-01-02
EP0166287A1 (de) 1986-01-02
IE851478L (en) 1985-12-16
BG61322B2 (bg) 1997-05-30
SK278401B6 (en) 1997-04-09
MY103021A (en) 1993-04-30
DK170440B1 (da) 1995-09-04
SG80192G (en) 1992-12-04
CA1254215A (en) 1989-05-16
PT80641A (de) 1985-07-01
CY1670A (en) 1993-10-10
GR851399B (pt) 1985-11-25
ES544204A0 (es) 1987-06-01
US4758579A (en) 1988-07-19
AU578703B2 (en) 1988-11-03
PT80641B (de) 1987-04-28
HK86894A (en) 1994-09-02
AU4364085A (en) 1985-12-19
IE58117B1 (en) 1993-07-14
NZ212415A (en) 1989-03-29
CZ281242B6 (cs) 1996-07-17
DK268285D0 (da) 1985-06-13
IL75400A0 (en) 1985-10-31
DE3572488D1 (en) 1989-09-28
NL950030I2 (nl) 1996-12-02
PH23729A (en) 1989-11-03
EP0166287B1 (de) 1989-08-23
DK268285A (da) 1985-12-17
ES8705875A1 (es) 1987-06-01

Similar Documents

Publication Publication Date Title
IL75400A (en) Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IL71310A0 (en) Benzimidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL83467A0 (en) Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
IL78111A0 (en) Sulfur-containing 5-substituted benzimidazole derivatives,their preparation and pharmaceutical compositions containing them
IL81172A0 (en) N-containing fused heterocyclic compounds,processes for the preparation thereof and pharmaceutical compositions comprising the same
AU7227587A (en) Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
IL96019A0 (en) Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL75120A0 (en) New pyrrolobenzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing them
IL80670A (en) Bicyclic sulfonamide derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
ZA859756B (en) Peptide-aldehydes,process for the preparation thereof and pharmaceutical compositions containing the same
IL83892A (en) (1h-imidazol-1-ylmethyl)substituted benzimidazole derivatives,their preparation and pharmaceutical compositions containing them
IL72085A0 (en) 13alpha-alkylylgonanes,processes for their preparation and pharmaceutical compositions containing the same
IL84446A0 (en) 3-pyrrolidinylthio-1-azabicyclo-(3.2.0)hept-2-ene-2-carboxylic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL81950A0 (en) 2-azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof processes for the preparation thereof and pharmaceutical compositions containing them
IL83760A (en) 3-pyrazoliomethyl-3- cephem-4-carboxylate derivatives, process for the preparation thereof, and pharmacetuical compositions containing the same
IL84589A0 (en) Pyrrolobenzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing them
IL92425A0 (en) Alpha-d-glucofuranose derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
IL62039A0 (en) Imidazoline derivative,processes for the preparation thereof and pharmaceutical compositions containing the same
IL84913A0 (en) Alkanesulfonanilide derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
IL73840A0 (en) 5-pyrimidinecarboxamides and thiocarboxamides,processes for the preparation thereof and pharmaceutical compositions containing the same
IL88903A (en) Indolylpiperidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL87563A (en) Isoxazole-b-carboline derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL78576A0 (en) 5-pyrimidinecarboxamide,processes for the preparation thereof and pharmaceutical compositions containing same
IL70488A0 (en) Fluoromethylthiooxacephalosporins,processes for the preparation thereof and pharmaceutical and veterinary compositions containing the same
IL64880A0 (en) Imidazoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
EXP Patent expired